Ethris and Heqet Therapeutics announce Collaboration

Collaboration will harness the potential of non coding RNAs (ncRNAs) in regenerating heart tissue

14-Nov-2023 - Ethris GmbH and Heqet Therapeutics, a biotechnology spin-out company from King’s College London active in the field of regenerative medicine, announced a collaboration agreement to harness the potential of ncRNA for heart tissue regeneration following acute myocardial infarction (heart attack) ...

Cipla EU to Invest EUR 15 million in Ethris

Cipla & Ethris partner for the development of mRNA-based therapies

02-Jan-2023 - Cipla Limited announced that its wholly owned UK subsidiary, Cipla (EU) Limited has signed definitive agreements for equity investment of EUR 15 million in Ethris GmbH, a global leader in delivering mRNAs directly to the respiratory system including administration by inhalation. The investment ...

Neurimmune and Ethris plan to develop inhaled mRNA-based antibody therapy for the treatment of Covid-19

Companies expect to initiate clinical testing in 2020

03-Apr-2020 - Neurimmune AG and Ethris GmbH announced an exclusive partnership to develop mRNA-encoded, neutralizing anti-SARS-CoV-2 antibodies administered by inhalation for the treatment of Covid-19. The collaboration brings together Neurimmune’s expertise in developing human antibodies based on ...

Ethris announces research based alliance on SNIM modified RNA with Shire

09-Jan-2013 - Ethris GmbH and Shire announce the initiation of a research based alliance focused on the development and commercialization of novel RNA-based therapeutics. Many devastating human diseases are the result of an inability of the body’s cells to make specific proteins that have an essential function ...